Research Notes
Highly potent oncology work could raise Small Molecule CDMO Services' growth because antibody-drug conjugates and targeted oncology agents drive demand for OEL band 5 containment suites, while Lonza, Siegfried, and Carbogen Amcis put more than USD 300 million into new HPAPI lines during 2024-2025, a sign that rivals are building the same capacity.
Jiuzhou built facilities for highly potent compounds featuring two OEB 5 lines and two OEB 4 lines. Jiuzhou Pharmaceutical's 2025 annual revenue reached 5.51B, reflecting 6.74% growth.
Growth in the small-molecule CDMO market is steady rather than explosive, so the service's outlook depends on the share it captures of that growth rather than on the market itself accelerating. The market is projected to rise from USD 194.58 billion in 2025 to USD 207.16 billion in 2026 and reach USD 290.32 billion by 2031, a 6.98% compound annual growth rate over 2026-2031.
Patent expiries threaten USD 150 billion in branded revenue through 2027, accelerating API outsourcing as originators shift toward asset-light production that favors external manufacturing partners. Geopolitical risk and the 2024 US BIOSECURE Act are realigning supply chains away from single-country dependence toward multi-node networks across North America, India, and Europe. Phase III capacity utilization already exceeds 85%, forcing sponsors to reserve early and lock into multi-year, multi-service agreements.
Small Molecule CDMO Services gives a small-molecule drug sponsor one contract partner for the whole path from preclinical chemical manufacturing and control through phase I/II/III clinical trials and new drug applications to global marketing, for customers worldwide.
The line delivers that path through a multi-site manufacturing network of over 50 production lines housed in large specialized workshops, multipurpose workshops and pilot plants, with kilogram- to tonne-scale manufacturing capability. Its production facilities use cGMP-qualified API production equipment that handles high-pressure dehydrogenation and cryogenic reactions. It also operates production facilities built for highly potent compounds, with two OEB 5 and two OEB 4 production lines.
Regulatory findings, not price, are the risk that could break the case, because a GMP lapse brings import scrutiny that disrupts finished-drug supply across a sponsor's lines. In 2025 the EMA flagged eight Asian facilities for GMP lapses, foreshadowing tighter import scrutiny. FDA warning letters to Gland Pharma, Fresenius Kabi and Intas Pharma in 2024 disrupted 15-20 finished-drug lines and boosted sponsor audit outlays by roughly 25%.
Compliance spending absorbs up to 12% of CDMO operating budgets, crowding out discretionary capital spending on technology upgrades and acting as an overhang for margin expansion. Geopolitical risk and the 2024 US BIOSECURE Act spur a realignment of supply chains away from single-country dependence toward multi-node networks spanning North America, India and Europe. Dual-sourcing mitigates schedule risk but lifts tech-transfer costs by up to 50% and complicates comparability filings.